LIFE CHANGING BREAKTHROUGHS

Aging isn’t a mystery. It can be understood and overcome.
We are the first and largest company dedicated to the research of longevity and aging in their totality. There are no fragmented solutions to a systemic breakdown.

There are eight pathways of aging. We have established and empowered our Daughter companies to tackle them.

our companies

Each Daughter company is taking a revolutionary approach to tackling one or more of the causes of aging, with a mission of making the solutions affordable and accessible to all.

Learn More

latest news

What if you could live to 115, and have those be productive, healthy and entirely enjoyable years? : A Q+A with Life Biosciences Chief Medical Advisor, Nir Barzilai, M.D.

What if you could live to 115, and have those be productive, healthy and entirely enjoyable years? Nir Barzilai, M.D., a renowned longevity expert, says it just may be possible. Listen to what he has to say about that, “zombie cells,” and what may be the cause of Alzheimer’s. By Adam Bluestein Nir Barzilai, M.D., … Continued

Read Full Article

Lua Technologies, A Subsidiary of Life Biosciences, Rated as the Leading Post-Acute Secure Messaging Solution by KLAS Research

LUA TECHNOLOGIES, A SUBSIDIARY OF LIFE BIOSCIENCES, RATED AS THE LEADING POST-ACUTE SECURE MESSAGING SOLUTION BY KLAS RESEARCH* Top Healthcare Data and Insights Company Uses Impartial Research for Key Industry Reports Used by Providers and Payers Worldwide   BOSTON, February 14 –Lua Technologies, a subsidiary of Life Biosciences Inc, has been ranked the highest scoring post-acute secure … Continued

Read Full Article

Life Biosciences Longevity Company, Prana, Receives Orphan Designation For PBT434 For Treatment of MSA

Prana Biotechnology Ltd (ASX: PBT, NASDAQ: PRAN) has today announced the US Food and Drug Administration (FDA) has granted Orphan Drug designation for its lead molecule, PBT434, for the treatment of Multiple System Atrophy (MSA). This is the first time the FDA has granted orphan designation to a drug for the treatment of MSA. Orphan Drug … Continued

Read Full Article

Life Biosciences Announces Closing Of $50 Million Series B Financing Round

BOSTON, Jan. 15, 2019 /PRNewswire/ — Life Biosciences has announced the closing of a Series B financing round of $50 million, according to Tristan Edwards, chief executive officer and co-founder. The Company initially targeted a $25 million round but upsized to meet investor demand. The proceeds of the investment will be used to continue Life Biosciences’ and its Daughter Companies’ … Continued

Read Full Article

View All